A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells

Biomater Sci. 2020 Mar 31;8(7):1973-1980. doi: 10.1039/c9bm01975h.

Abstract

We evaluate the application of surfactant-free liquid-phase exfoliated MoS2 nanosheets as a nanoplatform for a cancer detection and treatment system equipped with an antibody-antigen based recognition element. Employing antigen-antibody binding, we increased the probability of the endocytosis of MoS2 nanosheets into CAIX expressing cells by 30%. The nanosheets are functionalized with a specific antibody M75, which forms an antigen-antibody complex with CAIX. The bioconjugation of MoS2 nanosheets involves biocompatible components with low cytotoxicity, verified in the tested cell lines by fluorescence-based cell viability assay. The cellular internalization is quantified by flow cytometry, while the internalization is confirmed by label-free confocal Raman imaging. Raman measurements show increased lysosomal activity in the proximity of the internalized nanoplatforms.

MeSH terms

  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / pharmacology*
  • Antigens, Neoplasm
  • Carbonic Anhydrase IX / antagonists & inhibitors*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Disulfides / chemistry*
  • Flow Cytometry
  • Humans
  • Molybdenum / chemistry*
  • Nanostructures
  • Neoplasms / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Disulfides
  • M75 monoclonal antibody
  • Molybdenum
  • CA9 protein, human
  • Carbonic Anhydrase IX
  • molybdenum disulfide